BRPI0711310B8 - composto inibidor de p38 map cinase, composição farmacêutica compreendendo o mesmo e uso do mesmo - Google Patents

composto inibidor de p38 map cinase, composição farmacêutica compreendendo o mesmo e uso do mesmo

Info

Publication number
BRPI0711310B8
BRPI0711310B8 BRPI0711310A BRPI0711310A BRPI0711310B8 BR PI0711310 B8 BRPI0711310 B8 BR PI0711310B8 BR PI0711310 A BRPI0711310 A BR PI0711310A BR PI0711310 A BRPI0711310 A BR PI0711310A BR PI0711310 B8 BRPI0711310 B8 BR PI0711310B8
Authority
BR
Brazil
Prior art keywords
map kinase
radical
optionally substituted
formula
pharmaceutical composition
Prior art date
Application number
BRPI0711310A
Other languages
English (en)
Inventor
Festus Charles Moffat David
Pintat Stephane
John Davies Stephen
Original Assignee
Chroma Therapeutics Ltd
Macrophage Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0608855A external-priority patent/GB0608855D0/en
Priority claimed from GB0613914A external-priority patent/GB0613914D0/en
Application filed by Chroma Therapeutics Ltd, Macrophage Pharma Ltd filed Critical Chroma Therapeutics Ltd
Publication of BRPI0711310A2 publication Critical patent/BRPI0711310A2/pt
Publication of BRPI0711310B1 publication Critical patent/BRPI0711310B1/pt
Publication of BRPI0711310B8 publication Critical patent/BRPI0711310B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

composto inibidor de p38 map cinase, composição farmacêutica compreendendo o mesmo e uso do mesmo. a presente invenção refere-se aos compostos de fórmula (i) (i) são inibidores de p38 map cinase, e são, portanto, de utilidade no tratamento de, entre outros, condições inflamatórias incluindo artrite reumatóide e copd: em que: g é -n= ou -ch=; d é um radical arila ou heteroarila opcionalmente substituída mono- ou bi-cíclica tendo 5 a 13 membros; r6 é hidrogênio ou c1-c3 alquila opcionalmente substituída; p representa hidrogênio e u representa um radical de formula (ia); ou u representa hidrogênio e p representa um radical de formula -a-(ch2)z,-x1-l1-y-nh-chr1r2 em que a representa um radical mono ou bicíclico carbocíclico ou heterocíclico divalente opcionalmente substituído tendo 5 a 13 membros; z, y, l1, e x1 são como definidos na especificação; r1 é um grupo acido carboxílico (-cooh), ou um grupo éster que é hidrolisável por um ou mais enzimas esterase intracelulares a um grupo ácido carboxílico; e r2 é uma cadeia lateral de um aminoácido alfa natural ou não natural.
BRPI0711310A 2006-05-04 2007-05-01 composto inibidor de p38 map cinase, composição farmacêutica compreendendo o mesmo e uso do mesmo BRPI0711310B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0608855A GB0608855D0 (en) 2006-05-04 2006-05-04 Inhibitors of MAP kinase enzymes
GB0608855.3 2006-05-04
GB0613914.1 2006-07-13
GB0613914A GB0613914D0 (en) 2006-07-13 2006-07-13 Inhibitors of p38 map kinase
PCT/GB2007/001596 WO2007129040A1 (en) 2006-05-04 2007-05-01 p38 MAP KINASE INHIBITORS

Publications (3)

Publication Number Publication Date
BRPI0711310A2 BRPI0711310A2 (pt) 2011-12-06
BRPI0711310B1 BRPI0711310B1 (pt) 2020-12-15
BRPI0711310B8 true BRPI0711310B8 (pt) 2021-05-25

Family

ID=38268953

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0711310A BRPI0711310B8 (pt) 2006-05-04 2007-05-01 composto inibidor de p38 map cinase, composição farmacêutica compreendendo o mesmo e uso do mesmo

Country Status (15)

Country Link
US (1) US8044211B2 (pt)
EP (1) EP2013175B9 (pt)
JP (1) JP5340918B2 (pt)
KR (1) KR101429780B1 (pt)
CN (1) CN102942520B (pt)
AU (1) AU2007246869B2 (pt)
BR (1) BRPI0711310B8 (pt)
CA (1) CA2650970C (pt)
CY (1) CY1118518T1 (pt)
DK (1) DK2013175T5 (pt)
ES (1) ES2605727T3 (pt)
HU (1) HUE033281T2 (pt)
NZ (1) NZ573348A (pt)
PT (1) PT2013175T (pt)
WO (1) WO2007129040A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
EA017198B1 (ru) * 2006-10-30 2012-10-30 Хрома Терапьютикс Лтд. Гидроксаматы в качестве ингибиторов гистон-деацетилазы
SI2170848T1 (sl) 2007-06-27 2015-01-30 Astrazeneca Ab Derivati pirazinona in njihova uporaba pri zdravljenju bolezni pljuč
WO2009060160A1 (en) * 2007-11-07 2009-05-14 Chroma Therapeutics Ltd. P38 map kinase inhibitors
GB0803747D0 (en) 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation
JP5555186B2 (ja) * 2008-02-29 2014-07-23 クロマ セラピューティクス リミテッド ｐ３８ＭＡＰキナーゼ阻害剤
JP5627574B2 (ja) 2008-06-03 2014-11-19 インターミューン， インコーポレイテッド 炎症性および線維性疾患を治療するための化合物および方法
AR073711A1 (es) 2008-10-01 2010-11-24 Astrazeneca Ab Derivados de isoquinolina
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
GB201211310D0 (en) 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
NZ706717A (en) 2012-10-17 2018-02-23 Macrophage Pharma Ltd Tert-butyl n-[2-{ 4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2h)-yl]-3,5-difluorophenyl} ethyl]-l-alaninate or a salt, hydrate or solvate thereof
GB201306901D0 (en) * 2013-04-16 2013-05-29 Chroma Therapeutics Ltd Combination
JP6525437B2 (ja) 2014-04-02 2019-06-05 インターミューン， インコーポレイテッド 抗線維性ピリジノン
GB201713975D0 (en) 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003223953A1 (en) 2002-03-14 2003-09-22 Bayer Healthcare Ag Monocyclic aroylpyridinones as antiinflammatory agents
AU2006243000B2 (en) * 2005-05-05 2011-05-26 Macrophage Pharma Limited Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase
JP5555186B2 (ja) * 2008-02-29 2014-07-23 クロマ セラピューティクス リミテッド ｐ３８ＭＡＰキナーゼ阻害剤

Also Published As

Publication number Publication date
AU2007246869B2 (en) 2012-10-18
DK2013175T3 (en) 2017-02-20
KR20090014187A (ko) 2009-02-06
KR101429780B1 (ko) 2014-08-18
CN102942520B (zh) 2015-03-04
AU2007246869A1 (en) 2007-11-15
CA2650970C (en) 2014-09-16
CN102942520A (zh) 2013-02-27
BRPI0711310B1 (pt) 2020-12-15
PT2013175T (pt) 2017-02-14
WO2007129040A1 (en) 2007-11-15
EP2013175B1 (en) 2016-11-09
ES2605727T9 (es) 2020-12-11
NZ573348A (en) 2012-01-12
US8044211B2 (en) 2011-10-25
BRPI0711310A2 (pt) 2011-12-06
EP2013175A1 (en) 2009-01-14
JP2009535385A (ja) 2009-10-01
JP5340918B2 (ja) 2013-11-13
CY1118518T1 (el) 2017-07-12
DK2013175T5 (da) 2020-12-21
US20090099185A1 (en) 2009-04-16
HUE033281T2 (en) 2017-11-28
ES2605727T3 (es) 2017-03-16
CA2650970A1 (en) 2007-11-15
EP2013175B9 (en) 2020-11-11

Similar Documents

Publication Publication Date Title
BRPI0711310B8 (pt) composto inibidor de p38 map cinase, composição farmacêutica compreendendo o mesmo e uso do mesmo
MX2020013416A (es) Compuestos de coumarina sustituidos con amina terciaria y sus usos como etiquetas fluorescentes.
ECSP055910A (es) Nuevos acidos carboxilicos y sus esteres, medicamentos que contienen estos compuestos y procedimientos para su preparacion
BR112017005767A2 (pt) composições de limpeza contendo uma polieteramina
PE20151764A1 (es) Derivados de pirrolo[2,3-d]pirimidina
EA201071232A1 (ru) Триазины как ингибиторы киназы pi3 и mtor
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
AR082109A1 (es) Derivados de bipiridilo
MX2011011485A (es) Sulfonamidas nematocidas.
ECSP056232A (es) Nuevos compuestos
BRPI1009333B8 (pt) compostos inibidores de beta-secretase, seus usos, bem como composição farmacêutica
PE20140970A1 (es) Derivados de 6-ciclobutil-1,5-dihidro-pirazol [3,4-d) pirimidin-4-ona y su uso como inhibidores de pde9a
EA201100189A1 (ru) Гетероарильные производные в качестве ингибиторов dgat1
CY1111269T1 (el) Ρυθμιστες βενζιμιδαζολης του vr1
WO2009109991A3 (en) Novel hydrazide containing tyrosine kinase inhibitors
EA201001414A1 (ru) Производные азетидина и их применение
CO6420344A2 (es) Derivados de triazolopiridina como inhibidores de proteínas cinasas activadas por mitogeno p38 (map)
EA201300436A8 (ru) Совместные кристаллы и соли ингибиторов ccr3
BRPI0809542A8 (pt) Compostos derivados de indol tendo atividade de inibição de cpla2, composição farmacêutica, e métodos de produção dos referidos compostos
CO6280421A2 (es) Bifosfatos de alquilo de 2 a 5 atomos de carbonoimidazol
PL2144909T3 (pl) [2,6]-Naftyrydyny użyteczne jako inhibitory kinaz białkowych
EA201170224A1 (ru) Новые производные имидазо[1,2-a]пиримидинов, способ их получения, их применение в качестве лекарственных средств, фармацевтические композиции и новое применение, в частности, в качестве ингибиторов мет
BR112018069712A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a.
ATE493110T1 (de) Kosmetische zusammensetzung zur stimulierung der synthese der proteine der basalmembran
DE502006008710D1 (de) Substituierte tetrahydroisochinoline als mmp-inhibitoren, verfahren zu ihrer herstellung und ihre verwendung als medikament

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: MACROPHAGE PHARMA LIMITED (GB)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/05/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2721 DE 28-02-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.